Takeda Pharmaceutical (NYSE:TAK) Cut to Buy at Wall Street Zen

Takeda Pharmaceutical (NYSE:TAK) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday.

Other equities research analysts also recently issued reports about the stock. Morgan Stanley assumed coverage on shares of Takeda Pharmaceutical in a research note on Tuesday, January 13th. They issued an “overweight” rating for the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. Finally, Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. One investment analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold”.

Takeda Pharmaceutical Price Performance

Takeda Pharmaceutical stock opened at $17.84 on Friday. The stock has a market capitalization of $56.75 billion, a price-to-earnings ratio of 74.32 and a beta of 0.01. Takeda Pharmaceutical has a 52-week low of $12.99 and a 52-week high of $18.82. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.65 and a current ratio of 1.19. The stock’s 50 day moving average price is $17.65 and its two-hundred day moving average price is $15.66.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Thursday, January 29th. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.40. The company had revenue of $6.75 billion during the quarter, compared to analyst estimates of $7.81 billion. Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. On average, equities analysts predict that Takeda Pharmaceutical will post 1.64 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Valeo Financial Advisors LLC grew its stake in Takeda Pharmaceutical by 6.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 11,220 shares of the company’s stock worth $175,000 after buying an additional 632 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Takeda Pharmaceutical by 3.8% during the 3rd quarter. Franklin Resources Inc. now owns 19,458 shares of the company’s stock valued at $285,000 after buying an additional 713 shares in the last quarter. Private Trust Co. NA raised its position in shares of Takeda Pharmaceutical by 84.7% during the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after buying an additional 783 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Takeda Pharmaceutical by 5.3% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 16,927 shares of the company’s stock worth $248,000 after acquiring an additional 850 shares during the last quarter. Finally, Sanctuary Advisors LLC grew its position in Takeda Pharmaceutical by 4.0% in the fourth quarter. Sanctuary Advisors LLC now owns 23,626 shares of the company’s stock worth $368,000 after acquiring an additional 912 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.